Study of edaravone dexborneol for acute stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had an ischemic (clot-caused) stroke and can start the study medicine within 48 hours of symptoms starting.
- Your stroke is moderate to severe, with a certain level of disability in an arm or leg.
- You were able to do daily activities without help before the stroke (mRS score 0 or 1).
- You have not already taken edaravone dexborneol for this stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the safety and effectiveness of edaravone, a neuroprotective drug, in people who have had a mild to moderate stroke in the front part of the brain within the last 48 hours. It aims to see if this drug can help protect the brain from further damage.
This trial tests if a sublingual (under the tongue) medication called Edaravone Dexborneol can help stroke patients who are being transferred from one hospital to another for a specialized procedure to remove a clot.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This study tests whether a new drug called QD202 can help protect the brain and improve recovery when given alongside standard clot-busting therapy (thrombolysis) for acute ischemic stroke. You would be in the trial if you had a stroke in the last 24 hours and are receiving or planning to receive thrombolytic treatment.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
This trial tests a drug called Aleeto in people who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) within the last 72 hours. It aims to see if Aleeto can improve recovery and reduce disability.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.